Bullock A, et al. - A phase II study is performed to assess the efficacy and safety of capecitabine/oxaliplatin (CAPOX) in patients with locally advanced and metastatic pancreatic ductal adenocarcinoma (PDAC) treated in the first and second lines. Findings reveal that CAPOX is an active regimen and is associated with acceptable toxicity in patients with advanced PDAC. When studying this characteristically ill population, researchers recommend giving careful consideration to response endpoints and outcome measures.